The Supreme Court declined to hear Teva Pharmaceuticals USA’s challenge to a $235 million award to GlaxoSmithKline in a patent dispute over a generic heart drug.
Read the full post on Becker's Hospital Review - Healthcare News
Supreme Court rejects Teva's 'skinny label' case
